A potent and selective SAM-competitive PRMT5 inhibitor
Catalog #: B2749 | abID:

Product Details

Alternate Name (2R,3R,4S,5R)-2-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-hydroxy(phenyl)methyl)tetrahydrofuran-3,4-diol, (R)-5′-phenyl-7-deazaadenosine; 6-amino-9-[(R)-5′-phenyl(ribofuranosyl)]-7-deazapurine; LLY283
Peptide Sequence N/A
Appearance White to off-white solid
CAS # 2040291-27-6
Molecular Formula C₁₇H₁₈N₄O₄
Molecular Weight 342.35
Purity ≥98% by HPLC
Solubility >50 mg/ml DMSO
InChi InChI=1S/C17H18N4O4/c18-15-10-6-7-21(16(10)20-8-19-15)17-13(24)12(23)14(25-17)11(22)9-4-2-1-3-5-9/h1-8,11-14,17,22-24H,(H2,18,19,20)/t11-,12+,13-,14-,17-/m1/s1
PubChem CID 122669401
Handling Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Storage Conditions -20°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.


LLY-283 is a potent, selective protein arginine methyltransferase 5 (PRMT5) inhibitor (IC50 = 22 nM). It is selective for PRMT5 over a panel of 32 methyltransferases, including PRMT4, -6, and -7 at 1 μM. LLY-283 reduces proliferation of various breast, gastric, hematological, lung, skin, and ovarian cancer cell lines (IC50s = 3-30 nM).

Why buy BioVision Products?
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.